MACROGENICS INC
MGNX evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $275.2M
- Lead Asset:
- IMGC936 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for MGNX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MGNX
MacroGenics (MGNX) is a clinical-stage biopharmaceutical company developing antibody-based cancer therapeutics, with a recent shift to a leaner operating model after selling its manufacturing operations in mid-2026.
Key risk: Capital dependency
BioSniper Score
Based on 4 of 6 signals
Market Cap
$275.2M
Cash Runway
—
Lead Asset
IMGC936 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 20 clinical trials · 1 FDA decision for MACROGENICS INC.
MacroGenics (MGNX) is a clinical-stage biopharmaceutical company developing antibody-based cancer therapeutics, with a recent shift to a leaner operating model after selling its manufacturing operations in mid-2026.
- Cash & equivalents of $113.9M as of 2026-06-30 [sec].
- Total revenue of $32.8M and net income of $19.5M for the period ended 2026-06-30 [sec].
- Shareholders' equity of $42.9M as of 2026-06-30 [sec].
- Sold its manufacturing operations in July 2026 for $122.5M and transitioned to a fully outsourced model with a workforce of approximately 140 people [news · published 2026-08-13].
- Pipeline includes clinical-stage programs such as MGC026 (B7-H3 ADC), lorigerlimab (PD-1 × CTLA-4), and MGC028 (ADAM9 ADC), plus preclinical programs [sec_mda · as of 2026-08-14].
What works
- Extended cash runway to 2028 following the $122.5M sale of manufacturing operations [news · published 2026-07-27].
- Three FDA-approved products (ZYNYZ, MARGENZA, TZIELD) that were out-licensed or sold to partners provide potential royalty streams [sec_mda · as of 2026-08-14].
- Multiple clinical data catalysts in 2026, including MGC026 and lorigerlimab presentations at ESMO and MGC028 preliminary results expected late 2026 [news · published 2026-08-13].
What to weigh
- As a clinical-stage company, MacroGenics has primarily funded operations through equity offerings and collaboration revenue, with no guarantee of future capital availability [sec_mda · as of 2026-08-14].
- The company's ability to execute its operating plans depends on continued access to capital and successful collaborations; failure to secure new arrangements could require reassessment of capital needs [sec_mda · as of 2026-08-14].
- Stock volatility has been observed around clinical data releases, indicating market sensitivity to trial outcomes [news · published 2026-07-27].
From the filings
Quoted directly from source documents.
Sale of manufacturing operations for $122.5M
“Announced sale of manufacturing operations (July 2026) for $122.5 million”
News · August 13, 2026
Three FDA-approved products out-licensed or sold
“three products approved by the FDA: ZYNYZ ® (retifanlimab-dlwr), an anti-PD-1 monoclonal antibody (mAb) that the Company out-licensed; MARGENZA ® (margetuximab-cmkb), an anti-HER2 mAb that the Company sold to a partner; and TZIELD ® (teplizumab-mzwv), an anti-CD3 mAb that the Company sold to a partner.”
SEC MD&A · August 14, 2026
Extended cash runway to 2028
“extended cash runway to 2028”
News · July 27, 2026
Risks & what to watch (3)›
Key risks
- Capital dependency — Future operations rely on continued capital access; no assurance of new funding on acceptable terms [sec_mda · as of 2026-08-14].
- Clinical trial outcomes — Stock volatility around clinical data releases highlights sensitivity to trial results [news · published 2026-07-27].
- Collaboration reliance — Revenue and development depend on collaborations; failure to perform could limit product value [sec_mda · as of 2026-08-14].
What to watch
- Data presentations at ESMO 2026 for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4) [news · published 2026-08-13].
- Preliminary clinical results for MGC028 (ADAM9 ADC) expected in late 2026 [news · published 2026-08-13].
- First patient enrollment for MGC030 after IND clearance [news · published 2026-08-13].
- Financial performance under the new lean operating model following the CDMO sale [news · published 2026-08-13].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run MACROGENICS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MACROGENICS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 7.06 · 0% dilution
Lead: Approved
2 candidates
No upcoming catalysts tracked
0 buys · 1 sell (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 19, 2026- % of float
- 6.2%
- Days to cover
- 2.4
- Shares short
- 3,778,755
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MGNX short interestGovernance
Frequently asked questions
What is the AI investment thesis for MACROGENICS INC?
MacroGenics (MGNX) is a clinical-stage biopharmaceutical company developing antibody-based cancer therapeutics, with a recent shift to a leaner operating model after selling its manufacturing operations in mid-2026.
What is MACROGENICS INC's lead drug candidate?
MACROGENICS INC's most advanced tracked candidate is IMGC936 (Phase 1) for ADAM9-expressing tumors (solid tumors).
Who is the CEO of MACROGENICS INC?
Mr. Eric Blasius Risser is the chief executive officer of MACROGENICS INC (MGNX).
Where is MACROGENICS INC headquartered?
MACROGENICS INC (MGNX) is headquartered in Rockville, MD, United States.
What therapeutic areas does MACROGENICS INC focus on?
MACROGENICS INC develops therapies across Oncology, Immunology, Infectious Disease, Dermatology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.